1-10 of 10
Richard S Levy, MD
Close
Sort by
Journal Articles

Long-Term Outcomes Of Ruxolitinib Therapy In Patients With Myelofibrosis: 3-Year Update From COMFORT-I

Srdan Verstovsek, MD, PhD, Ruben A. Mesa, MD, Jason Gotlib, MD, MS, Richard S. Levy, MD, Vikas Gupta, MD, FRCP, FRCPath, John F. Dipersio, MD, PhD, John V. Catalano, MD, Michael W. Deininger, MD, PhD, Carole B. Miller, MD, Richard T. Silver, Moshe Talpaz, MD, Elliott F. Winton, MD, Jimmie H. Harvey, Jr., MD, Murat O. Arcasoy, MD, Elizabeth Hexner, MD, Roger M. Lyons, MD, Ronald Paquette, MD, Azra Raza, MD, Kris Vaddi, PhD, William Sun, PhD, Wei Peng, PhD, Victor A. Sandor, MD, CM, Hagop M. Kantarjian, MD
Journal: Blood
Blood (2013) 122 (21): 396.
https://doi.org/10.1182/blood.V122.21.396.396
Published: 2013
Journal Articles

Efficacy, Hematologic Effects, and Dose of Ruxolitinib in Myelofibrosis Patients with Low Starting Platelet Counts (50–100 × 10 9 /L): A Comparison to Patients with Normal or High Starting Platelet Counts

Moshe Talpaz, MD, Ronald Paquette, MD, PhD, Lawrence Afrin, MD, Solomon Hamburg, MD, PhD, Katarzyna Jamieson, MD, Howard Terebelo, DO, Gregory Ortega, MD, Roger M. Lyons, MD, Ramon V. Tiu, MD, BS, Elliott F. Winton, MD, Kavita Natrajan, MD, Olatoyosi Odenike, MD, Wei Peng, PhD, Victor A. Sandor, MD, CM, Peter O'Neill, MBA, CCRP, Sue Erickson-Viitanen, PhD, Lance Leopold, MD, Richard S Levy, MD, Hagop M Kantarjian, MD, Srdan Verstovsek, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 176.
https://doi.org/10.1182/blood.V120.21.176.176
Published: 2012
Journal Articles

Long-Term Outcome of Ruxolitinib Treatment in Patients with Myelofibrosis: Durable Reductions in Spleen Volume, Improvements in Quality of Life, and Overall Survival Advantage in COMFORT-I

Srdan Verstovsek, MD, PhD, Ruben A. Mesa, Jason Gotlib, Richard S. Levy, MD, Vikas Gupta, MD, FRCP, FRCPath, John F. DiPersio, MD, PhD, John V. Catalano, MD, Michael W.N. Deininger, MD, PhD, Carole B. Miller, MD, Richard T. Silver, MD, Moshe Talpaz, MD, Elliott F. Winton, MD, Jimmie H. Harvey, Jr., MD, Murat O. Arcasoy, MD, Elizabeth O. Hexner, MD, Roger M. Lyons, MD, Ronald Paquette, MD, PhD, Azra Raza, MD, Kris Vaddi, PhD, Susan Erickson-Viitanen, PhD, William Sun, PhD, Victor A. Sandor, MD, CM, Hagop M. Kantarjian, MD
Journal: Blood
Blood (2012) 120 (21): 800.
https://doi.org/10.1182/blood.V120.21.800.800
Published: 2012
Journal Articles

Long-Term Safety, Efficacy, and Survival Findings From Comfort-II, a Phase 3 Study Comparing Ruxolitinib with Best Available Therapy (BAT) for the Treatment of Myelofibrosis (MF)

Francisco Cervantes, MD, Jean-Jacques Kiladjian, MD, PhD, Dietger Niederwieser, Andres Sirulnik, MD, PhD, Viktoriya Stalbovskaya, PhD, Mari McQuity, RN, MPH, Deborah S. Hunter, PhD, Richard S. Levy, MD, Francesco Passamonti, MD, Tiziano Barbui, MD, Giovanni Barosi, MD, Heinz Gisslinger, MD, Alessandro M. Vannucchi, MD, Laurent Knoops, MD, PhD, Claire N Harrison, DM FRCP FRCPath
Journal: Blood
Blood (2012) 120 (21): 801.
https://doi.org/10.1182/blood.V120.21.801.801
Published: 2012
Journal Articles

Health-Related Quality of Life and Symptoms in Myelofibrosis Patients Treated with Ruxolitinib Versus Best Available Therapy

Claire N. Harrison, DM, FRCP, FRCPath, Jean-Jacques Kiladjian, MD, PhD, Haifa Kathrin Al-Ali, MD, Heinz Gisslinger, MD, Laurent Knoops, MD, PhD, Roger J. Waltzman, MD, Estella T. Mendelson, BSRN, MBA, Xiaolei Zhou, Catherine Copley-Merriman, Deborah S. Hunter, PhD, Richard S. Levy, MD, Francisco Cervantes, MD, PhD, Francesco Passamonti, MD, Alessandro M. Vannucchi, MD, Tiziano Barbui, MD, Giovanni Barosi, MD
Journal: Blood
Blood (2011) 118 (21): 795.
https://doi.org/10.1182/blood.V118.21.795.795
Published: 2011
Journal Articles

Clinical Burden and Progression of Myelofibrosis in a Controlled Study Population of Placebo-Treated Patients (COMFORT-I)

Srdan Verstovsek, MD, PhD, Ruben A. Mesa, MD, Jason Gotlib, MD, MS, Richard S. Levy, MD, Vikas Gupta, MD, FRCP, FRCPath, John F. DiPersio, MD, PhD, John Catalano, MD, Michael W. Deininger, Carole B. Miller, MD, Richard T. Silver, MD, Moshe Talpaz, MD, Elliott F. Winton, MD, Jimmie H. Harvey, Jr., MD, Murat O. Arcasoy, MD, Elizabeth Hexner, MD, Roger M. Lyons, MD, Ronald Paquette, MD, PhD, Azra Raza, MD, Kris Vaddi, PhD, Sue Erickson-Viitanen, PhD, William Sun, PhD, Victor A. Sandor, MD, CM, Hagop M. Kantarjian
Journal: Blood
Blood (2011) 118 (21): 5146.
https://doi.org/10.1182/blood.V118.21.5146.5146
Published: 2011
Journal Articles

Consistent Benefit of Ruxolitinib Over Placebo in Spleen Volume Reduction and Symptom Improvement Across Subgroups and Overall Survival Advantage: Results From COMFORT-I

Srdan Verstovsek, MD, PhD, Ruben A. Mesa, MD, Jason Gotlib, MD, MS, Richard S. Levy, MD, Vikas Gupta, MD, FRCP, FRCPath, John F. DiPersio, MD, PhD, John Catalano, MD, Michael W. Deininger, Carole B. Miller, MD, Richard T. Silver, MD, Moshe Talpaz, MD, Elliott F. Winton, MD, Jimmie H. Harvey, Jr., MD, Murat O. Arcasoy, MD, Elizabeth Hexner, MD, Roger M. Lyons, MD, Ronald Paquette, MD, PhD, Azra Raza, MD, Kris Vaddi, PhD, Sue Erickson-Viitanen, PhD, William Sun, PhD, Victor A. Sandor, MD, CM, Hagop M. Kantarjian
Journal: Blood
Blood (2011) 118 (21): 278.
https://doi.org/10.1182/blood.V118.21.278.278
Published: 2011
Journal Articles

Ruxolitinib Provides Reductions in Splenomegaly Across Subgroups: An Analysis of Spleen Response in the COMFORT-II Study

Claire N. Harrison, DM, FRCP, FRCPath, Jean-Jacques Kiladjian, MD, PhD, Heinz Gisslinger, MD, Dietger Niederwieser, MD, Francesco Passamonti, MD, Roger J. Waltzman, MD, Norbert Hollaender, PhD, Deborah S. Hunter, PhD, Richard S. Levy, MD, Laurent Knoops, MD, PhD, Francisco Cervantes, MD, PhD, Alessandro M. Vannucchi, MD, Tiziano Barbui, MD, Giovanni Barosi, MD
Journal: Blood
Blood (2011) 118 (21): 279.
https://doi.org/10.1182/blood.V118.21.279.279
Published: 2011
Journal Articles

Associations Between Improvements in Myelofibrosis (MF) Symptoms and Quality of Life Measures with Splenomegaly Reduction in COMFORT-I: A Randomized, Double-Blind, Phase III Trial of the JAK1 and JAK2 Inhibitor Ruxolitinib Versus Placebo in Patients with MF,

Ruben A. Mesa, MD, Jason Gotlib, MD, MS, Vikas Gupta, MD, FRCP, FRCPath, John F. DiPersio, MD, PhD, John Catalano, MD, Michael W. Deininger, Alan Shields, PhD, Carole B. Miller, MD, Richard T. Silver, MD, Moshe Talpaz, MD, Elliott F. Winton, MD, Jimmie H. Harvey, Jr., MD, Thomas Hare, PhD, Sue Erickson-Viitanen, PhD, William Sun, PhD, Victor A. Sandor, MD, CM, Richard S. Levy, MD, Hagop M. Kantarjian, Srdan Verstovsek, MD, PhD
Journal: Blood
Blood (2011) 118 (21): 3842.
https://doi.org/10.1182/blood.V118.21.3842.3842
Published: 2011
Journal Articles

Comparison of the Efficacy of Placebo and Best Available Therapy for the Treatment of Myelofibrosis in the COMFORT Studies

Ruben A. Mesa, MD, Srdan Verstovsek, MD, PhD, Francisco Cervantes, MD, PhD, Roger J. Waltzman, MD, Estella T. Mendelson, BSRN, MBA, Nicolas Martin, MS, William Sun, PhD, Victor A. Sandor, MD, CM, Richard S. Levy, MD, Claire N. Harrison, DM, FRCP, FRCPath
Journal: Blood
Blood (2011) 118 (21): 1753.
https://doi.org/10.1182/blood.V118.21.1753.1753
Published: 2011